SIM
RAPP

Sandia Investment Management’s Rapport Therapeutics RAPP Stock Holding History

Sandia Investment Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$182K Hold
6,000
– – 0.45% 81
2025
Q3 		$178K Buy
+6,000
New +$107K 0.53% 67
2025
Q1 		– Sell
-5,000
Closed -$88.7K – 125
2024
Q4 		$88.7K Hold
5,000
– – 0.17% 92
2024
Q3 		$102K Hold
5,000
– – 0.16% 75
2024
Q2 		$116K Buy
+5,000
New +$116K 0.14% 72

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Sandia Investment Management's RAPP Position: Q4 2025 in Review

Sandia Investment Management held its Rapport Therapeutics (RAPP) position steady in Q4 2025 at 6,000 shares worth $182K. The position accounts for 0.45% of the portfolio, ranked #81.

Sandia Investment Management first reported a position in RAPP in Q2 2024 and has held it in 5 quarters since. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Sandia Investment Management held 6,000 shares of Rapport Therapeutics worth $182K as of Q4 2025.
  • Sandia Investment Management left its Rapport Therapeutics share count unchanged in Q4 2025.
  • Rapport Therapeutics made up 0.45% of Sandia Investment Management's portfolio in Q4 2025, its #81 holding.
  • Sandia Investment Management first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Sandia Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.